<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271072</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104111</org_study_id>
    <nct_id>NCT04271072</nct_id>
  </id_info>
  <brief_title>CSF/Serum Biomarkers in Predicting PND/Persistent Pain After Cesarean</brief_title>
  <official_title>The Role of Cerebrospinal Fluid and Serum Inflammatory Biomarkers in Predicting Perinatal Depression and Persistent Pain After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate if inflammatory biomarkers in the blood and cerebrospinal fluid
      (CSF) are associated with the development of perinatal depression and/or persistent pain
      after cesarean delivery.

      This study will obtain CSF and blood samples in 70 parturients. All parturients will be
      assessed for perinatal depression and persistent pain, and the presence/absence of these
      outcomes will be correlated to changes in the inflammatory biomarkers within the samples
      collected. If present, consistent changes in biomarkers correlating with perinatal depression
      or persistent pain may be utilised as a predictive tool and facilitate early treatment for
      these conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent pain and perinatal depression (PND) contribute significantly to maternal morbidity
      and mortality after cesarean delivery. Neuroinflammation has been associated with both
      persistent pain and perinatal depression, and may therefore be a common etiological process,
      however, little is known of the association between neuroinflammation and persistent pain or
      PND in parturients undergoing cesarean delivery.

      Aim 1: To compare neuroinflammatory cytokine profiles (in CSF and plasma samples within 48
      hours after surgery) between the cohort of parturients that develop the composite outcome of
      persistent pain or PND (defined below), versus the cohort of parturients that did not develop
      this outcome.

      Aim 2. To determine the correlation between the neuroinflammatory cytokine profiles of CSF
      and plasma.

      This is a prospective cohort study of 70 adult parturients undergoing elective cesarean
      delivery at Duke University Hospital. After obtaining informed consent, baseline demographic
      data, the Edinburgh Postnatal Depression Scale (EPDS), mechanical temporal summation (MTS),
      and pain-pressure threshold (PPT) tests will be administered. During IV cannulation, 10ml of
      blood will be collected, and up to 10ml CSF will be collected during spinal anesthesia. After
      cesarean delivery, pain scores, analgesia requirements, and data on adverse events will be
      collected. Additional 10ml of blood will be collected within 48 hours post-surgery during
      inpatient hospital stay. During the routine 6-week postnatal follow up, EPDS scores will be
      recorded, and at 3-months, EPDS and persistent pain assessment will be conducted over the
      phone.

      Based on a composite endpoint of persistent pain (pain at 3 months after surgery) or PND
      (EPDS of 10 or greater, during pregnancy or within 3 months after delivery), parturients will
      be stratified into &quot;study&quot; or &quot;control&quot; cohorts. Using a validated multiplex quantitative
      proteomic approach, candidate biomarkers will be quantified and correlated against the
      composite outcome using two-sided Mann-Whitney U test. Correlation between CSF and plasma
      cytokines will be assessed using spearman correlation. The exploratory aim will be analyzed
      with generalized linear models.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perinatal depression</measure>
    <time_frame>Up to 3 months after delivery</time_frame>
    <description>Edinburgh postnatal depression scale &gt;=10 (minimum 0, maximum 30, increasing score indicates higher likelihood of depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent pain: Pain score</measure>
    <time_frame>Up to 3 months after delivery</time_frame>
    <description>Pain score &gt;=3 at pelvic or lower abdominal areas (minimum 0, maximum 10, higher score indicates greater pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory cytokines/biomarkers</measure>
    <time_frame>Up to 24 hours after surgery</time_frame>
    <description>Biomarkers from CSF and plasma samples will be quantified using Meso Scale Discovery multiplex kit (K15210D), for:
CRP, Eotaxin, Eotaxin-3, FGF (basic), ICAM-1, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, PlGF, SAA, TARC, Tie-2, TNF-α, TNF-β, VCAM-1, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1.
The levels of these biomarkers will be compared between the group with depression/persistent pain, versus the group without depression/persistent pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF compared to plasma inflammatory cytokines/biomarkers</measure>
    <time_frame>Preoperative samples</time_frame>
    <description>Biomarkers will be quantified using Meso Scale Discovery multiplex kit (K15210D), for:
CRP, Eotaxin, Eotaxin-3, FGF (basic), ICAM-1, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, PlGF, SAA, TARC, Tie-2, TNF-α, TNF-β, VCAM-1, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1
The CSF and plasma levels of these biomarkers will be compared within each group (group with depression/persistent pain, versus group without depression/persistent pain)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Perinatal Depression</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <description>Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:
perinatal depression (Edinburgh postnatal depression scale &gt;=10 during pregnancy or within 3 months after delivery), and/or
persistent pain (pain score &gt;=3 at pelvic or lower abdominal areas at 3 months after delivery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:
perinatal depression (Edinburgh postnatal depression scale &gt;=10 during pregnancy or within 3 months after delivery), AND
persistent pain (pain score &gt;=3 at pelvic or lower abdominal areas at 3 months after delivery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and CSF samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary care hospital, specialist obstetric unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) class 2 and 3

          -  English speaking

          -  18 years or older

          -  Singleton pregnancy

          -  Gestational age &gt; 37 weeks

          -  Scheduled cesarean delivery under spinal or combined spinal epidural anesthesia

        Exclusion Criteria:

          -  Intravenous drug or chronic opioid use

          -  Anti-depressant or anxiolytic drug use

          -  Allergy to standard of care drugs

          -  Cesarean delivery under general anesthesia or epidural anesthesia

          -  Pre-eclampsia needing magnesium sulfate

          -  Chronic PO/IV analgesic or glucocorticoids

          -  History of chronic pain syndromes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only pregnant parturients are eligible</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Yurashevich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Yurashevich</last_name>
    <phone>919-684-8111</phone>
    <email>mary.yurashevich@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Yurashevich</last_name>
      <phone>919-684-8111</phone>
      <email>mary.yurashevich@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017 May;135(5):373-387. doi: 10.1111/acps.12698. Epub 2017 Jan 25.</citation>
    <PMID>28122130</PMID>
  </reference>
  <reference>
    <citation>Miller ES, Sakowicz A, Roy A, Yang A, Sullivan JT, Grobman WA, Wisner KL. Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression. Am J Obstet Gynecol. 2019 Mar;220(3):271.e1-271.e10. doi: 10.1016/j.ajog.2018.12.015. Epub 2018 Dec 14.</citation>
    <PMID>30557551</PMID>
  </reference>
  <reference>
    <citation>Osborne LM, Monk C. Perinatal depression--the fourth inflammatory morbidity of pregnancy?: Theory and literature review. Psychoneuroendocrinology. 2013 Oct;38(10):1929-52. doi: 10.1016/j.psyneuen.2013.03.019. Epub 2013 Apr 20. Review.</citation>
    <PMID>23608136</PMID>
  </reference>
  <reference>
    <citation>Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010 Mar 1;67(5):446-57. doi: 10.1016/j.biopsych.2009.09.033. Epub 2009 Dec 16.</citation>
    <PMID>20015486</PMID>
  </reference>
  <reference>
    <citation>Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology. 2018 Aug;129(2):343-366. doi: 10.1097/ALN.0000000000002130. Review.</citation>
    <PMID>29462012</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroinflammation</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Cesarean delivery</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asphyxia Neonatorum</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

